A Phase III Study to Evaluate the Efficacy and Safety of Fruquitinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer
Phase of Trial: Phase III
Latest Information Update: 28 Nov 2019
Price : $35 *
At a glance
- Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms FRUTIGA
- Sponsors Hutchison MediPharma
- 28 Nov 2019 According to a Chi-Med (Hutchison China MediTech Limited ) media release, in April 2019, the company conducted an interim analysis of this study for futility. The analysis evaluated PFS and OS trends after six months of therapy for the first 100 patients recruited into the study. The Independent Data Monitoring Committee (IDMC) recommended to continue the study without changes.
- 28 Nov 2019 According to a Chi-Med (Hutchison China MediTech Limited ) media release, enrollment of this study is expected to be completed in mid-2020 with top line results in early 2021.
- 15 Oct 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Apr 2019.